

Conatus Pharmaceuticals Investor Relations Department 16745 W. Bernardo Drive Ste 200 San Diego, CA 92127 United States

Visit IR website ☐ Sign-up for Email alerts ☐

NASDAQ: CNAT Last Trade: 5.70 Trade Time: 2:19 PM ET Sep 20, 2017 Change: 0.10 ♣ (+1.766%) Day Range 5.56 - 5.75 52-Week Range 1.45 - 9.40 Volume 109,038

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Stock Performance



Press Releases [View all]

Aug 31, 2017

Conatus Pharmaceuticals Appoints Keith W. Marshall as Executive Vice President, Chief Operating Officer and Chief Financial Officer

Aug 29, 2017

Conatus to Present at Rodman & Renshaw Global Investment Conference

Aug 14, 2017

Conatus Announces Completion of Enrollment in ENCORE-NF Phase 2b Clinical Trial of Emricasan in Patients with NASH Fibrosis

Aug 2, 2017

<u>Conatus Pharmaceuticals Reports Second Quarter 2017</u> Financial Results and Program Updates

Jul 26, 2017

Conatus Pharmaceuticals to Report Second Quarter 2017 Financial Results

Financials [View all]

Second Quarter Financial Results

Mar 16, 2017

Annual Report (10-K)

Apr 28, 2017

Proxy Statement (DEF 14A)

Aug 4, 2017

Quarterly Report (10-Q)

Mav 5. 2017

Quarterly Report (10-Q)

Nov 8, 2016

Quarterly Report (10-Q)